Winter 2018

Phase I Study of Ipilimumab Combined with Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients with Brain Metastases

Noelle L. Williams
Thomas Jefferson University, noelle.williams@jefferson.edu

Evan J. Wuthrick
Ohio State University

Hyun Kim, MD
Thomas Jefferson University, hyun.kim@jefferson.edu

Joshua D. Palmer
Ohio State University

Shivank Garg
Thomas Jefferson University, shivank.garg@jefferson.edu

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/jhnj
Let us know how access to this document benefits you

Recommended Citation
Williams, Noelle L.; Wuthrick, Evan J.; Kim, MD, Hyun; Palmer, Joshua D.; Garg, Shivank; Eldredge-Hindy, Harriet B.; Daskalakis, Constantine; Feeney, Kendra J.; Mastrangelo, Michael; Kim, Lyndon; Sato, Takami; Olencki, Thomas; Liebner, David A.; Farrell, MD, Christopher J.; Evans, James J.; Judy, MD, Kevin; Andrews MD, David W.; Dicker, Adam MD, PhD; Werner-Wasik, Maria; Shi, Wenyin; and Kendra, Kari L. (2018) "Phase I Study of Ipilimumab Combined with Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients with Brain Metastases," JHN Journal: Vol. 13 : Iss. 1 , Article 3.
DOI: https://doi.org/10.29046/JHNJ.013.1.003
Available at: https://jdc.jefferson.edu/jhnj/vol13/iss1/3

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University’s Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Phase I Study of Ipilimumab Combined with Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients with Brain Metastases

Authors
Noelle L. Williams; Evan J. Wuthrick; Hyun Kim, MD; Joshua D. Palmer; Shivank Garg; Harriet B. Eldredge-Hindy; Constantine Daskalakis; Kendra J. Feeney; Michael Mastrangelo; Lyndon Kim; Takami Sato; Thomas Olencki; David A. Liebner; Christopher J Farrell, MD; James J. Evans; Kevin Judy, MD; David W. Andrews MD; Adam Dicker MD, PhD; Maria Werner-Wasik; Wenyin Shi; and Kari L. Kendra

This review article is available in JHN Journal: https://jdc.jefferson.edu/jhnj/vol13/iss1/3
Phase I Study of Ipilimumab Combined with Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients with Brain Metastases

Noelle L. Williams, MD1; Evan J. Wuthrick, MD2; Hyun Kim, MD2; Joshua D. Palmer, MD2; Shivank Garg, MD2; Harriet B. Eldredge-Hindy, MD2; Constantine Daskalakis, ScD2; Kendra J. Feeney, MD3; Michael J. Mastrangelo, MD3; Lyndon J. Kim, MD3; Takami Sato, MD, PhD3; Kari L. Kendra, MD4; Thomas Olencki, DO4; David A. Liebner, MD4; Christopher J. Farrell, MD4; James J. Evans, MD4; Kevin D. Judy, MD4; David W. Andrews, MD4; Adam P. Dicker, MD4; Maria Werner-Wasik, MD4; Wenyin Shi, MD4

1Department of Radiation Oncology, Thomas Jefferson University, Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA.
2Department of Radiation Oncology, Ohio State University, Columbus, OH.
3Department of Radiation Oncology, Baystate Medical Center, Springfield, MA.
4Department of Biostatistics, Thomas Jefferson University, Philadelphia, PA.
5Department of Medical Oncology, Thomas Jefferson University and Sidney Kimmel Cancer Center, Philadelphia, PA.
6Division of Medical Oncology, Ohio State University, Columbus, OH.
7Department of Neurosurgery, Thomas Jefferson University and Sidney Kimmel Cancer Center, Philadelphia, PA.

Running Title
ipilimumab with RT for Melanoma Brain Metastases

Funding sponsor
Bristol-Myers Squibb

Conflict of interest
none

Key Words
immunotherapy, ipilimumab, metastatic melanoma, brain metastases

ABSTRACT

Purpose: We performed a phase I study to determine the maximum tolerable dose (MTD) and safety of ipilimumab with stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT) in patients with brain metastases (BM) from melanoma.

Methods: Based on intracranial (IC) disease burden, patients were treated with WBRT (Arm A) or SRS (Arm B). Ipilimumab starting dose was 3 mg/kg (every 3 weeks, starting on day 3 of WBRT or 2 days after SRS). Ipilimumab was escalated to 10 mg/kg using a two-stage, 3+3 design. The primary endpoint was to determine the MTD of ipilimumab combined with radiotherapy. Secondary endpoints were overall survival (OS), IC and extracranial (EC) control, progression free survival (PFS), and toxicity. This trial is registered with ClinicalTrials.gov, number NCT01703507.

Results: Characteristics of the 16 patients enrolled between 2011 and 2014 were: mean age, 60; median BM, 2 (1 to >10); number with EC disease, 13 (81%). Treatment included WBRT (n=5), SRS (n=11), ipilimumab 3mg/kg (n=7), 10 mg/kg (n=9). Median follow-up was 8 months (Arm A) and 10.5 months (Arm B). There were 21 grade 1-2 neurotoxic effects with no dose-limiting toxicities (DLTs). One patient experienced grade 3 neurotoxicity prior to ipilimumab administration. Ten additional grade 3 toxicities were reported with gastrointestinal (n=5, 31%) as the most common. There were no grade 4/5 toxicities. Median PFS and OS, respectively, in Arm A were 2.5 months and 8 months, and in Arm B were 2.1 months and not reached.

Conclusion: Concurrent ipilimumab 10 mg/kg with SRS is safe. The WBRT arm was closed early due to slow accrual, but demonstrated safety with ipilimumab 3 mg/kg. No patient experienced DLT. Larger studies with ipilimumab 10 mg/kg and SRS are warranted.

INTRODUCTION

Brain metastases (BM) occur in more than half of patients with advanced melanoma, and central nervous system disease burden often contributes to their death.1,2 The historic median survival of patients with BM from melanoma is 4.7 months.3 Traditional BM treatment options includes surgery, whole brain radiation therapy (WBRT), and stereotactic radiosurgery (SRS), and can prevent neurological decline and may also improve overall (OS).4,5 There has been increasing interest in radiotherapy (RT) combined with immunotherapy (IT) with growing evidence supporting a potential synergistic effect. It remains unclear the role that this synergism has on toxicity.8 Activated T-cells and antibodies targeting tumor-associated antigens (TAAs) detected in blood from cancer patients supports an active role for an anti-tumor immune response.9 T-cell infiltrates in melanoma have prognostic significance, and when identified within nodal metastases, predict benefit in patients treated with neoadjuvant interferon-α-2b.10-13 Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), is a negative regulator of T-cell-mediated anti-tumor immune responses and therefore represents a critical checkpoint, controlling both response duration and intensity.14-16 Ipilimumab (MDX-010, Bristol-Myers Squibb) is a fully human monoclonal antibody
Ipilimumab was administered intravenously over 90 minutes once every 3 weeks for 4 total doses and was dose-escalated independently in each arm with no intra-patient escalation. The FDA approved dose of 3 mg/kg was the starting dose. Rationale for ipilimumab dose escalation to 10mg/kg was based on findings from the randomized, double-blind, phase 2 dose-ranging study of ipilimumab monotherapy demonstrating the best overall response rate in the 10 mg/kg group (11.1%, 95% CI 4.9-10.7) versus the 3 mg/kg group (4.2%, 95% CI 0.9-11.7), suggesting further investigation of this higher dose.26 Following the initial 4 treatments, maintenance dosing was offered to patients without unacceptable toxicity (refractory grade > 3 immune-related adverse events [irAEs]) at the same dose level given every 12 weeks until disease progression, toxicity requiring discontinuation, or consent withdrawal.

Dose-Limiting Toxicity
Adverse events (AEs) were recorded with the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v.4). Dose-limiting toxicity (DLT) was defined as any grade 3 or higher treatment related toxicity occurring within 30 days of completing RT. Any neurological toxicity of grade 3, 4, or 5 was considered dose-limiting (except symptoms present prior to study enrollment or expected sequela of surgery or SRS). All patients were followed for AEs for 4 weeks following the last dose of ipilimumab. Intratumoral hemorrhage
was defined as new or worsening signs of bleeding within the irradiated tumor or cavity volume.

Assessment of Efficacy
Contrast-enhanced MRI of the brain was performed at week 7 and then every 2 months for 1 year, then every 3 months. All MRIs were interpreted using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) and immune-related response criteria (irRC). Overall response using irRC was classified as immune-related complete response (irCR), partial response (irPR), stable disease (irSD), or progressive disease (irPD) based on the predefined combination of parameters. For evaluation of EC disease, CT of the chest, abdomen, and pelvis was performed at week 7 and 13 following enrollment, and every 3 months subsequently.

Statistical Methodology
A two-stage 3+3 accrual design was used at each dose considered with goal accrual of up to 12 patients for each arm, with up to 9 patients accrued from either Thomas Jefferson University or Ohio State University. Initially 3 patients were enrolled at the 3 mg/kg level. If none of these patients experienced a DLT, enrollment continued to the 10 mg/kg level. If 1 of the 3 experienced toxicity at that level, 3 additional patients were accrued to the initial dose level. While waiting to complete the toxicity assessment for each triplet, additional patients could be accrued on the same dose, although their outcome was not considered for dose escalation purposes. No patient was treated at a higher dose until the 3 or 6 patients completed their toxicity evaluation period at the current dose.

Data were analyzed separately for the two arms. Kaplan-Meier estimates for OS and PFS were computed in Stata 14 (StataCorp, College Station, TX). PFS was analyzed from the date of SRS (or first day of WBRT) to the date of recurrence or progression. OS was analyzed from the date of first RT fraction to the date of death or last patient contact (censored observation). Analysis of EC control, new BM development, and safety/tolerance was done separately for each arm. All subjects enrolled in the study who received at least one dose of ipilimumab were analyzed.

Role of the Funding Source
This study was funded by Bristol-Myers Squibb (New York City, NY) which provided the study drug and worked with the senior authors in the design and analysis. All authors jointly approved this work for submission and confirm the accuracy of the data. No additional authors not listed contributed to this work. All authors affirm that this trial was performed in accordance with the protocol and all amendments.

RESULTS

Patient Characteristics
Of the 26 patients screened for the trial, 17 signed informed consent and were deemed eligible. One patient never received protocol therapy due to deteriorating health following consent. Sixteen patients received study therapy and were analyzed (Figure 2). Table 1 summarizes the patient and clinical characteristics, separately for the two arms. Overall, the mean age at time of BM diagnosis was 60 (SD, 5-13) and 75% of the patients were male. There were 8 patients each with ECOG performance status of 0 and 1. Nine patients (56%) had initial BM surgery. Thirteen patients (81%) had EC metastases at the time of BM diagnosis and 5 (38%) received RT for their EC disease.

In Arm A (WBRT, n=5), the median number of lesions was 6 (range, 1 to >10) and the dose was 30 Gy in 10 fractions for all patients. In Arm B (SRS, n=11, the median number of lesions was 2 (range, 1 to 3) and the median dose was 24 Gy (range, 15 to 24 Gy). In total, 20 lesions/cavities were treated with SRS with a median planning target volume of 3.25 cc per individual lesion (range, 0.1-22.7 cc). The median per patient treatment volume was 8.5 cc (range 0.5-29.2 cc). The median number of completed cycles of ipilimumab was as follows: 4 (range, 2 - 4+14 maintenance) for dose level 3 mg/kg (n=7), and 3 (range, 2 - 4...
Table 1. Baseline Patient, Lesion, and Treatment Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n=16)</td>
<td></td>
</tr>
<tr>
<td>Mean age at IC diagnosis (range)</td>
<td>60 (37-75)</td>
</tr>
<tr>
<td>Sex, No. (%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>13 (81%)</td>
</tr>
<tr>
<td>Female</td>
<td>3 (19%)</td>
</tr>
<tr>
<td>ECOG performance status (n)</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Number with extracranial metastases</td>
<td>13 (81%)</td>
</tr>
<tr>
<td>Number with pre-RT surgery</td>
<td>8 (50%)</td>
</tr>
<tr>
<td>Radiation technique</td>
<td></td>
</tr>
<tr>
<td>WBRT</td>
<td>5 (31%)</td>
</tr>
<tr>
<td>Median # lesions (range)</td>
<td>6 (1-&gt;10)</td>
</tr>
<tr>
<td>SRS</td>
<td>11 (19%)</td>
</tr>
<tr>
<td>Median # lesions (range)</td>
<td>2 (1-3)</td>
</tr>
<tr>
<td>Median dose, Gy (range)</td>
<td>24 (15-24)</td>
</tr>
<tr>
<td>Ipilimumab</td>
<td></td>
</tr>
<tr>
<td>Dose</td>
<td>3 mg/kg</td>
</tr>
<tr>
<td>Median # cycles completed (range)</td>
<td>4 (2-4+14 maintenance)</td>
</tr>
<tr>
<td>Dose</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>Median # cycles completed (range)</td>
<td>3 (2-4)</td>
</tr>
<tr>
<td>Median length of follow-up after RT, months (range)</td>
<td>9.1 (2-37)</td>
</tr>
</tbody>
</table>

Toxicity

Ipilimumab in combination with RT was well tolerated. There were 21 grade 1-2 neurotoxic effects including the following: headache (n=6, 37.5%), nausea/vomiting (n=3, 18.8%), subclinical intracranial hemorrhage (n=4, 25%), dizziness (n=1, 6.3%), vision changes (n=1, 6.3%), tinnitus/hearing loss (n=3, 18.8%), facial palsy (n=1, 6.3%), weakness/neuropathy (n=1, 6.3%), and seizure (n=1, 6.3%). There were no documented reports of pseudoprogression in our small sample of patients.

One patient experienced headache prompting emergency room evaluation, categorized as a grade 3 neurotoxic event. This toxicity occurred following SRS but prior to first IT administration and was therefore not considered a dose-limiting toxicity (DLT), but rather, an effect of surgery and SRS. The patient went on to receive 4 doses of ipilimumab plus one maintenance cycle prior to disease progression. There were no additional grade 3 neurotoxicities.

Table 2 summarizes the AEs in detail. In addition to the neurotoxicity above, there were 10 additional grade 3 toxicities, including gastrointestinal most commonly (n=5, 31%). There were no grade 4 or 5 toxicities. Of note, no patients experienced radionecrosis.

Progression-Free Survival and Overall Survival

Median follow-up time was 8.0 months in Arm A (range, 3.5 to 24.1) and 10.5 months in Arm B (range, 1.8 to 36.8) from first day of RT to last follow-up or death. At time of analysis, no patients were still on treatment. Fourteen patients in total progressed and/or died during the study’s follow-up (5/5 = 100% in Arm A and 9/11 = 82% in Arm B). Thirteen patients had IC progression (including the 6 who subsequently died). Median time to IC progression was 2.53 months (WBRT, range 0.3-18) versus 2.45 months (SRS, range 1-37). Overall response intracranially as defined by the irRC (15...
with treatment sites as follows: lung (n=2), thoracic/lumbar vertebrae and lower leg soft tissue metastasis (n=1). Of the 3 patients with no EC disease at the time of BM diagnosis, all 3 remained without EC disease at 2 month follow-up. Overall, 6 patients experienced EC progression at 2 months, 5 patients had stable disease, 3 patients continued with no EC disease, 1 patient had a partial response (after having her EC disease treated), and 1 patient did not receive systemic imaging at the 2 month time point.

Seven patients developed new BM (as differentiated from previously treated BM) on follow-up imaging (Arm A, n=1 and Arm B, n=6) with the median time from first RT fraction to new BM diagnosis of 1.9 months (range, 0.97 to 8.2). The median time from first RT fraction to development of new BM in the one patient having received WBRT was 8.2 months.

**DISCUSSION**

To the best of our knowledge, we report the first prospective phase I study evaluating concurrent ipilimumab with SRS or WBRT for patients with melanoma BM. The toxicity profile of escalating doses of ipilimumab demonstrated no grade 4/5 toxicity, radionecrosis, or DLTs. Ipilimumab 10 mg/kg with SRS is safe and we recommend this dose for further study with concurrent SRS. Additional phase I studies will be necessary to determine the safety of WBRT with ipilimumab 10 mg/kg, as we had to terminate this part of the trial due to slow accrual, however safety was demonstrated with concurrent WBRT and ipilimumab 3 mg/kg.

CA184-04230 was a phase II trial that evaluated ipilimumab in patients with melanoma BM. Patients were specifically excluded from the trial if they received any RT within 14 days of ipilimumab and only 8% of patients had received prior SRS. There were no unexpected toxicities and activity was demonstrated particularly when BM were small and asymptomatic. However, this trial does not specifically evaluate the safety of concurrent RT and ipilimumab.

Hodi et al. reported a large study evaluating 676 patients randomized to receive ipilimumab 3 mg/kg in combination with an investigational peptide vaccine

---

**Table 2. Adverse effects in SRS (n=11) and WBRT (n=5) arms**

<table>
<thead>
<tr>
<th></th>
<th>Grade 1–2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SRS</td>
<td>WBRT</td>
<td>SRS</td>
</tr>
<tr>
<td>Headache</td>
<td>4</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Post-treatment subclinical intracranial hemorrhage</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Nausea, vomiting, abdominal pain</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Hearing loss, oitis, tinnitus</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Skin reaction, pruritus</td>
<td>2</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Insomnia</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Anorexia</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Hot flashes</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Constipation</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Visual changes</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Hypophylitis</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Alopecia</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Dizziness</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Bone pain</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Anemia</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Depression</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Lipase increase</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Weakness, neuropathy</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Seizure</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Facial palsy</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pleuritic pain, effusion</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Abbreviations: SRS=stereotactic radiosurgery; WBRT=whole brain radiation therapy.
Seven of the 13 patients treated concurrently had documented hemorrhage partially accounting for the enlargement and 2 lesions had documented recurrence. Of note, the IT was not standardized in this retrospective review and included ipilimumab, nivolumab, and pembrolizumab.32

Kiess et al.33 retrospectively reported response and toxicity on 46 patients with melanoma BM who received ipilimumab (3 mg/kg or 10 mg/kg) with SRS (median dose 21 Gy) between 2005 and 2011. Patients treated with SRS either before or during ipilimumab had improved OS compared to those having SRS afterward (1-year OS 56% vs 65% vs 40%, p=0.008). Moreover, only approximately 20% of patients experienced grade 3 or 4 toxicities. Interestingly, SRS before or during IT was more likely to be associated with a temporary increase in size or hemorrhage of the irradiated lesion, likely secondary to inflammation, and asymptomatic in the majority of cases.33 Most likely due to the small numbers in our study and the frequency of neurosurgical intervention prior to SRS (6/11 patients, 55%), we did not observe the same temporary lesional edema following combination therapy. Similarly, no lesions were deemed to undergo pseudoprogression following SRS.

When evaluating the effects of IT, EC disease control is also of interest. First described in the 1950s, the abscopal effect refers to the seldom-reported phenomenon of tumor regression of a secondary site following RT to a separate primary site.34 Seromic analysis and immunologic correlates of the abscopal effect in a patient with melanoma has demonstrated antigenic targets with increased antibody responses following RT.35 The surprising response achieved by the patient in this report provided new insight in the mechanisms of combination therapy. Our study evaluated EC control as a secondary endpoint with a similar hypothesis that IT delivered in close proximity to SRS may impact distant control. In our study, we did not observe the abscopal effect extracranially or intracranially at non-target sites.

Limitations of our study include slow accrual to Arm A, leading to its early closure. This arm did show safety with ipilimumab 3 mg/kg, however. An additional caveat to

(gp100), ipilimumab alone, or gp100 alone. OS was 10.0 months in patients receiving ipilimumab plus gp100, compared to 10.1 months in the ipilimumab alone arm and 6.4 months in the gp100 alone arm (p<0.001). Eighty-two patients (12.1%) had CNS disease in this study.18 This data is comparable to our study with the median OS not reached in the SRS arm and 8 months in the WBRT arm (median follow-up 10.5 and 8 months, respectively). Given that OS has not been reached in the SRS arm of our trial, we hypothesize that the timing of ipilimumab in close proximity to SRS may mechanistically promote duration and intensity of response in these patients, although this study is hypothesis-generating in that regard.

To this end, a recent report by Johnson et al.31 demonstrated the impact of systemic agents on the clinical outcomes of patients with BM. Although this review included patients with many primary tumor types, and a variety of agents (BRAF inhibitors, ipilimumab in patients with melanoma primaries), the authors did show that patients receiving IT with SRS compared to SRS alone had a median survival of 18 versus 7 months and a 1-year OS of 65% versus 30% (p<0.0001).31

In terms post-RT lesion size, reports with combined therapy have been conflicting. Qian et al.8 recently reported results regarding 313 melanoma BMs in 53 patients treated concurrently (defined as RT and IT delivery within 4 weeks of each other). IT was as follows: 54 patients (72%) received anti-CTLA-4 and 21 patients (28%) received anti-PD-1. No patients received combination IT. The median percent reduction in lesion volume was significantly greater for the concurrent group. The timing of IT and SRS did not appear to affect post-treatment lesion size.8 In this report, only 39 lesions in 24 patients demonstrated regrowth to >120% baseline volume. Authors concluded that the early response is greater and more rapid with concurrent therapy. There was not specific mention of tumor hemorrhage in this study.8 In contrast to this report, preliminary data reported by Shen et al. showed an increase in lesion size in 13 of 26 lesions treated concurrently (defined as IT starting “prior to or with SRS”).32 Lesion enlargement in the SRS alone cohort occurred with similar frequency.

![Figure 4. Overall survival for the SRS and WBRT patients](https://jdc.jefferson.edu/jhnj/vol13/iss1/3)

**Figure 4. Overall survival for the SRS and WBRT patients**
our study is that ipilimumab alone is no longer the standard of care for previously untreated advanced melanoma. First-line therapy is now either anti-programmed death 1 (PD-1) inhibitor monotherapy (pembrolizumab or nivolumab) or a combination of nivolumab with ipilimumab. This combination of therapies improved overall response rate and PFS as compared with either treatment alone, however, demonstrated significantly increased toxicity. Compared to single agent therapy, the effect of combination therapy on OS has not yet been demonstrated. Pembrolizumab alone demonstrated prolonged PFS and OS and had less high-grade toxicity as compared to ipilimumab in patients with advanced melanoma as demonstrated in the KEYNOTE-006 trial. Based on these results, future studies will need to address RT with combination checkpoint inhibitor therapy or pembrolizumab alone.

An additional limitation is the relatively short follow-up possibly limiting the capture of late toxicity. The median follow-up in the arm receiving SRS was 10.5 months which may be long enough to catch some, but not all cases of radionecrosis. A recent report by Colaco et al. evaluating 180 patients with BM who received radiosurgery with either cytotoxic chemotherapy, targeted therapy, or IT noted a significantly increased rate of radionecrosis or treatment-related imaging changes in the IT group (OR 2.40 [95% CI 1.06–5.44]; p = 0.03). The median follow-up was 11.7 months and 31% of patients had melanoma primaries. Of importance, 30% of patients received prior WBRT which increases one’s risk for subsequent radionecrosis following radiosurgery. For patients who received IT alone, median time to radionecrosis development was 10.2 months (range, 2.8–22.1 months), which is slightly shorter than the median follow-up in our SRS arm. Therefore, although our study does have relatively short follow-up, it is worthwhile to demonstrate that we have no documented cases of radionecrosis.

In an era where combined modality targeted therapy is becoming more promising and increasingly utilized, it is important to establish the safety profiles of these modalities. Our results demonstrate the safety of combining SRS with either ipilimumab 3 mg/kg or 10 mg/kg.

Future exploration of multi-agent immunotherapy in combination with SRS for melanoma BM is warranted, although currently there are no clinical trials open to accrual evaluating the safety and efficacy of this combination of treatment.

Table 3. Previously reported series of melanoma brain metastases treated with immunotherapy.

<table>
<thead>
<tr>
<th>Primary author</th>
<th>Year</th>
<th>Analysis type</th>
<th>Primary</th>
<th>Patients who got SRS (n)</th>
<th>IT agent/timing</th>
<th>Patients receiving IT and SRS (%)</th>
<th>Median survival (months)</th>
<th>OS</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knisely⁴¹</td>
<td>2012</td>
<td>Prospectively collected, retrospectively</td>
<td>melanoma</td>
<td>7</td>
<td>Ipilimumab (SRS first, n=16; IT first, n=11)</td>
<td>27 (35%)</td>
<td>21.3 (with IT) v. 4.9 (no IT)</td>
<td>2 year: 47.2% (with IT) v. 19.7% (no IT) p=0.044</td>
<td>Grade ≥3 toxicity NR</td>
</tr>
<tr>
<td>Johnson⁴</td>
<td>2015</td>
<td>retrospective</td>
<td>renal cell, melanoma, breast, colon, esophagus, lung</td>
<td>737</td>
<td>various agents (including BRAF inhibitors &amp; ipilimumab), IT concurrently or within 30 days of SRS</td>
<td>167 (23%)</td>
<td>18 (with IT) v. 7 (no IT)</td>
<td>1 year: 65% (with IT) v. 30% (no IT) p&lt;0.0001</td>
<td>Grade ≥3 toxicity NR</td>
</tr>
<tr>
<td>Kiess³</td>
<td>2015</td>
<td>retrospective</td>
<td>melanoma</td>
<td>46</td>
<td>Ipilimumab (concurrent, n=15; SRS first, n=19; IT first, n=12)</td>
<td>46 (100%)</td>
<td>12.4 (all patients)</td>
<td>1 year: 65% (concurrent) v. 56% (SRS before) v. 40% (IT before) p=0.008</td>
<td>1 year RR: 69% (concurrent) v. 64% (SRS before) v. 92% (IT before) p=0.003</td>
</tr>
<tr>
<td>Patel⁴²</td>
<td>2015</td>
<td>retrospective</td>
<td>melanoma</td>
<td>54</td>
<td>Ipilimumab (within 4 months of SRS)</td>
<td>20 (37%)</td>
<td>9 (1 of IT) v. 8.0 (no IT) p=0.84</td>
<td>NA</td>
<td>1 year LC: 71.4% (with IT) v. 92.3% (no IT) p=0.40</td>
</tr>
</tbody>
</table>

NR: not reported; IT: immunotherapy; RR: regional recurrence
REFERENCES


Corresponding Author
Wenyin Shi, MD, PhD
Department of Radiation Oncology
Sidney Kimmel Medical College
Thomas Jefferson University
Sidney Kimmel Cancer Center at Jefferson
111 South 11th Street, Suite G301
Philadelphia, PA 19107
P: 215-955-6702
F: 215-955-0412
E: wenyin.shi@jefferson.edu